Rasagiline Mesylate Tablets Market

Rasagiline Mesylate Tablets (Azilect) is an irreversible inhibitor of monoamine oxidase-B used as a monotherapy to treat symptoms in early Parkinson's disease or as an adjunct therapy in more advanced cases.

Rasagiline Mesylate Tablets Market contains market size and forecasts of Rasagiline Mesylate Tablets in global, including the following market information:

• Global Rasagiline Mesylate Tablets Market Revenue, 2017-2022, 2023-2028, ($ millions)
• Global Rasagiline Mesylate Tablets Market Sales, 2017-2022, 2023-2028, (M Pcs)
• Global top five Rasagiline Mesylate Tablets companies in 2021 (%)

The global Rasagiline Mesylate Tablets market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.

The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.

0.5 mg/Pcs Segment to Reach $ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Rasagiline Mesylate Tablets include Teva Pharmaceutical, Lundbeck, Sun Pharmaceutical, Apotex, Taj Pharma, Mylan, Takeda Pharmaceutical, Sandoz and Intas Pharmaceuticals, etc. In 2021, the global top five players have a share approximately % in terms of revenue.

We surveyed the Rasagiline Mesylate Tablets manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Rasagiline Mesylate Tablets Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (M Pcs)

Global Rasagiline Mesylate Tablets Market Segment Percentages, by Type, 2021 (%)

• 0.5 mg/Pcs
• 1 mg/Pcs

Global Rasagiline Mesylate Tablets Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (M Pcs)

Global Rasagiline Mesylate Tablets Market Segment Percentages, by Application, 2021 (%)

• Under 40 Years Old
• 40-65 Years Old
• Above 65 Years Old

Global Rasagiline Mesylate Tablets Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (M Pcs)

Global Rasagiline Mesylate Tablets Market Segment Percentages, By Region and Country, 2021 (%)

• North America
• US
• Canada
• Mexico
• Europe
• Germany
• France
• U.K.
• Italy
• Russia
• Nordic Countries
• Benelux
• Rest of Europe
• Asia
• China
• Japan
• South Korea
• Southeast Asia
• India
• Rest of Asia
• South America
• Brazil
• Argentina
• Rest of South America
• Middle East & Africa
• Turkey
• Israel
• Saudi Arabia
• UAE
• Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

• Key companies Rasagiline Mesylate Tablets revenues in global market, 2017-2022 (Estimated), ($ millions)
• Key companies Rasagiline Mesylate Tablets revenues share in global market, 2021 (%)
• Key companies Rasagiline Mesylate Tablets sales in global market, 2017-2022 (Estimated), (M Pcs)
• Key companies Rasagiline Mesylate Tablets sales share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

• Teva Pharmaceutical
• Lundbeck
• Sun Pharmaceutical
• Apotex
• Taj Pharma
• Mylan
• Takeda Pharmaceutical
• Sandoz
• Intas Pharmaceuticals
• Natco Pharma
• Ajanta Pharma
• Orchid Pharma
• Alkem Laboratories